All-new research in dermatology is available now – take a look at this month’s new and exclusive content on JDDonline.com:
- In a multicenter clinical study, investigators conduct an analysis of data on the Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
-
Authors evaluate Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia in a retrospective chart review of TA patients treated with ILK at an academic dermatology clinic.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
- The IL-17 pathway plays a crucial role in the immunopathogenesis and development of psoriasis in Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
-
A Survey of Dermatologists’ Preparedness for Natural and Manmade Disasters examines whether the dermatology field has advanced in its bioterrorism preparedness since a 2003 survey revealed 88% of dermatologists felt unprepared to respond to a biological attack.
View all February JDD content, including editor’s picks, supplements, CME activities, case reports, and more!
Read Now
You May Also Like
An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
INTRODUCTIONPsoriasis is a common, chronic, autoimmune skin disorder that, in its plaque form, is characterized by dry, red lesions with silvery scales that cause itching, dryness, and irritation.1 About 80%…
Dermatology Roundup: Newly FDA-Approved Cheek Filler, Molluscum Contagiosum Trial Results, Eating Disorders & Acne Vulgaris
By Allison Sit The Food and Drug Administration has approved Restylane Contour for cheek augmentation and correction of midface contour deficiencies in adults older than 21. Approval of the new…
